Exelixis Inc (E2XE34) Cotización

Epilepsy 
Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. We are currently developing azetukalner for the treatment of epile

I was not expecting you to reveal the personal information, just the date and shares but that’s okay:)

+0.0002 (44.44%) Volume: 225,155,817
Day Range: 0.00045 - 0.0008

Are you sad to see no one is dumping any shares?
Does it make you upset that everyone is holding tight?
Is it difficult to watch the BID move up & build?
Do you regret not grabbing .03's when they were available?

I have a solution for those uncomfortable feelings

The company also stated that their cash flow is improving and there is no need for convertible debt at this time. That is one of the biggest takeaways I got from this. We saw that in the Q3 numbers. 

Nah.  To easy to post truth to your ignorance nonsense.

-One MM to .006
-so thin
-big news on the way.
-best chart on the OTC
-biggest accumulation ever
-20 year audit coming.  You have to be a moron to think it's no coming. 

On and on

Ddog96 You are 100% right, perfect DD Let's those 2 CLOWNS 🤡 read it >>>>🫡

False assumptions built upon fallacious interpretations of technicals.
No basis for such assumptions as the technical readings are inaccurate.

Anyone have a good proven recipe for pumpkin pie? Can I use a sweetener instead of sugar? Best cream?

Looking like a small runway for stock takeoff if the company can get things cleaned up before mid December. Don’t let it close.

Knitting many things for presents thi

100% spot on in all respects. Thanks for sharing that.

Just like I had been stating here before, q1, Q2 2025 are going to hugely determine stock price. Based on what I heard in the spaces call, I expect the float to stay close to where it is now and to share price much closer to a penny. Anything under .002 is a steal rn, I firmly believe in the couple

Agree, these comments make a lot of sense, especially this part:

introduced investor questions around why HALO would pursue something seemingly so divergent from its current business.

Thank you very much for sharing this analysis, Maumar.

But if the MDASE

lookout MONDAY- here we come!
Baron Capital Enterprise, Inc. (OTC: $BCAP) anticipates providing updates for our shareholders on Monday. Stay tuned for further information.

There you go again, can't have a discussion without the need to attack someone personally instead of addressing the message which has no personal attacks. . So explain why VLDI does not provide more detail information about this 170 page report, like who are the experts endorsing the product and

I certainly disagree with that.
I search CDBT through ihub or OTC Markets using the ticker code and it comes up with China Dasheng Biotechnology Co everytime.
If you look through the filings, you see Cycclone Inc. but only as pending.
It won't be showing Cycclone Inc until FI

Has anyone seen this document before?

https://www.advfn.com/stock-market/NASDAQ/ELAB/stock-news/94972274/form-def-14c-other-definitive-information-statem

Nuke, not easy to give an ABC answer. First, one can say that medium intensity statins plus ezetimibe did show benefits over simply high intensity statins. But, this was a meta-analysis, and those are notorious since the authors decide what studies to pick and choose. Now the benefits over HIS by

👀👀no vol in a while--- we have a few watchers

$ASII There are about 10 Catalysts. Can anyone name them? 🤑

Of course it's name of the game, but you lied about "big news coming" to have people front load it so you can sell. 

Lol-  and you always side step the real discussion with other nonsense that's completely off topic. 

Yes indeed.

Nothing like a little ...or in some cases.... a lot of extra green :-D

MRES

Wayne is a clown and I'm about ready to put him on the Iggy Bus.

Per the article posted here, Adding to vendors' worries is Pemex's ongoing payment backlog. As of 2 October, Pemex's upstream division (PEP) owed Ps99bn ($5bn) to suppliers, with Ps81bn related to 2024 projects, Ps10.5bn from 2023 and Ps1.9bn from 2022, according to an internal document. Pemex's o